Page 3,635«..1020..3,6343,6353,6363,637..3,6403,650..»

Adult Stem Cell Research | Ray Flynn – Video

Posted: Published on September 12th, 2014

Adult Stem Cell Research | Ray Flynn Former Boston mayor Ray Flynn speaks about Catholic teaching on Adult Stem Cell Research, and his own advocacy on the issue. By: The CatholicTV Network … Continue reading →

Posted in Stem Cell Research | Comments Off on Adult Stem Cell Research | Ray Flynn – Video

Google Continues To Build Upon Its Life Sciences Ecosystem

Posted: Published on September 12th, 2014

Google has a mission to organize the worlds information and make it accessible to everyone. The companyis mostly known for its search engine and the largest mobile operating system, but you may not be aware that Google is also heavily involved in the life sciences sector. Google has invested in a number of biotech and life science companies through its venture capital arm, Google Ventures. Lift Labs Yesterday, Google acquired Lift Labs. Lift Labs is a company that has built a high-tech device handle, which can stabilize what is being held using an attachable spoon or fork. This type of device benefits someone that has Parkinsons Disease or Essential tremor (ET). The Lift Labs team is joining the Life Sciences division at Google[x], which is a skunkworks lab led by Google co-founder Sergey Brin. DNAnexus DNAnexus is a DNA sequencing data software company that works with several genome sequencing organizations to better understand human genetics contributing to heart disease and aging.Last year, DNAnexus partnered with Baylor College of Medicine to process 3,751 whole human genomes and 10,771 exomes. DNAnexus uses Amazon Web Services cloud computing to sequence DNA data and store it.GoogleVentures invested in DNAnexus$15 million Series B and $15 … Continue reading →

Posted in Human Genetics | Comments Off on Google Continues To Build Upon Its Life Sciences Ecosystem

Q&A Part 3 High Frequency Training Downside Vertical Leap Untrained Vs Genetics Tips For Cellulite – Video

Posted: Published on September 12th, 2014

Q A Part 3 High Frequency Training Downside Vertical Leap Untrained Vs Genetics Tips For Cellulite 0:15 Is it true that once you do high frequency training for a while (let's say squatting and pressing 4+ times a week), you really can't go back and train l... By: JuggernautFitnessTV … Continue reading →

Posted in Genetics | Comments Off on Q&A Part 3 High Frequency Training Downside Vertical Leap Untrained Vs Genetics Tips For Cellulite – Video

Primary care doctors reluctant to provide genetics assessment in routine care

Posted: Published on September 12th, 2014

PUBLIC RELEASE DATE: 11-Sep-2014 Contact: Mary Masson mfmasson@umich.edu 734-764-2220 University of Michigan Health System @UMHealthSystem Ann Arbor, Mich. Primary care providers report many challenges to integrating genetics services into routine primary care, according to research published today in Genetics in Medicine. Medical genetics medicine has traditionally been used to identify and diagnose rare diseases, but in the last decade it has been increasingly helpful in determining patients at risk for genetically-based conditions who can benefit from preventive health care, says the study's senior author, Beth Tarini, M.D., M.S., F.A.A.P., assistant professor of pediatrics at the University of Michigan Medical School and C.S. Mott Children's Hospital. "Genetics is not just about rare diseases and specialists. PCPs rely on genetics frequently during preventive care visits especially when taking family histories and assessing a patient's risk of more common, but chronic, diseases. So the fact that PCPs report many barriers to embracing and performing these tasks is concerning, " says Tarini, who is also an investigator at U-M's Child Health Evaluation & Research (CHEAR) Unit and co-medical director of the Genetics in Primary Care Institute (GPCI), a project of the American Academy of Pediatrics Tarini and her co-investigators conducted a systematic literature review … Continue reading →

Posted in Genetics | Comments Off on Primary care doctors reluctant to provide genetics assessment in routine care

Life Science 012: Genetic Engineering – Video

Posted: Published on September 12th, 2014

Life Science 012: Genetic Engineering Life Science 012: Genetic Engineering Lesson objectives: Explaining the concept and process of genetic engineering. By: SABC Education Shows … Continue reading →

Posted in Genetic Engineering | Comments Off on Life Science 012: Genetic Engineering – Video

Shaking Science with style from IMGGE University of Belgrade, Serbia – Video

Posted: Published on September 12th, 2014

Shaking Science with style from IMGGE University of Belgrade, Serbia Shaking Science with style made by the Institute of Molecular Genetics and Genetic Engineering (IMGGE), University of Belgrade, Belgrade Serbia Video made for the Competition The Art of Shaking... By: The Art of Shaking by Kuhner Shaker … Continue reading →

Posted in Genetic Engineering | Comments Off on Shaking Science with style from IMGGE University of Belgrade, Serbia – Video

” “: How University of Belgrade shake – Video

Posted: Published on September 12th, 2014

" ": How University of Belgrade shake Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade Serbia http://www.abtek.ru/home/news/161-novosti-kompanii/286-the-art-of-shaking http://vk.com/abtek... By: Abtek TV … Continue reading →

Posted in Genetic Engineering | Comments Off on ” “: How University of Belgrade shake – Video

Feds slow to respond to state GMO task force

Posted: Published on September 12th, 2014

Federal authorities have been slow to answer questions about genetic engineering regulations asked by an Oregon task force assembled by Gov. John Kitzhaber. Kitzhaber launched the task force early this year to write a report framing the controversy on genetically modified organisms and how theyre regulated in Oregon. Task force members held a teleconference in early June with representatives from the USDA, U.S. Environmental Protection Agency and U.S. Food and Drug Administration, which jointly regulate biotechnology. Task force members followed up with two sets of questions to clarify such issues as how the government increases tolerance levels of pesticides on biotech crops. They requested a response by mid-August. As of the task forces latest meeting on Wednesday, Sept. 3, only the FDA provided responses to the questions, according to state officials at the meeting. I personally am disappointed they have not been able to come back to us with concrete responses, says Ivan Maluski, director of Friends of Family Farmers, a group thats critical of federal oversight of biotechnology. Stephanie Page of the Oregon Department of Agriculture says representatives from USDA and EPA have apologized for the delay, citing the absences of key officials. It appears that some of the … Continue reading →

Posted in Genetic Engineering | Comments Off on Feds slow to respond to state GMO task force

27 – Gene Therapy by Jasmine Costa – Video

Posted: Published on September 12th, 2014

27 - Gene Therapy by Jasmine Costa 27 - Gene Therapy by Jasmine Costa. By: Bruce Rasmussen … Continue reading →

Posted in Gene Therapy | Comments Off on 27 – Gene Therapy by Jasmine Costa – Video

Rare disease biotech Xenon Pharmaceuticals files for a $52 million IPO

Posted: Published on September 12th, 2014

Xenon Pharmaceuticals, an early-stage biotech with a gene therapy discovery platform for rare diseases, filed on Wednesday with the SEC to raise up to $52 million in an initial public offering. Xenon has a number of collaboration and licensing agreements with large pharmaceuticals including Teva, Genentech and Merck for its preclinical research. The company's discovery platform was used to develop uniQure's Glybera treatment for orphan disease lipoprotein lipase deficiency, the first gene therapy approved in the EU. February IPO uniQure ( QURE ) priced above its range but ended the first day down 14% and now trades down 36% below the IPO price. Xenon is eligible to receive mid single-digit royalties on net sales of Glybera. Teva is in Phase 2 trials for a gene therapy discovered by Xenon that is being developed to treat osteoarthritis. Genentech was cleared to begin a Phase 1 trial for Xenon's pain treatment and Merck is in preclinical development for cardiovascular disease. Xenon also has a variety of preclinical therapies for both orphan diseases (such as Dravet Syndrome) and large-market conditions (including acne). Primary shareholders include Medpace (16%), Lipterx (11%), InterWest Partners (9%), Fidelity (7%), Invesco (5%) and CEO Simon Pimstone (4%). The Burnaby, … Continue reading →

Posted in Gene Therapy | Comments Off on Rare disease biotech Xenon Pharmaceuticals files for a $52 million IPO

Page 3,635«..1020..3,6343,6353,6363,637..3,6403,650..»